2,3-Dimethyl-1,4-di(propan-2-yl)pyrrolidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2,3-Dimethyl-1,4-di(propan-2-yl)pyrrolidine
• 英文别名: 2,3-dimethyl-1,4-di(propan-2-yl)pyrrolidine
• 化学式: C₁₂H₂₅N
• 分子量: 183.33
• InChiKey: RFSNCRGNOZSCPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] CELL-PROTECTIVE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS PROTECTEURS DE CELLULES ET LEUR UTILISATION
  申请人：ETH ZUERICH

  公开号：WO2018130537A1

  公开（公告）日：2018-07-19

  The present invention is directed to cell-protective, in particular, cardio- and renal-protective organic compounds, preferably to organic compounds that inhibit substrate phosphorylation by the G-protein-coupled receptor kinase 2 (GRK2, ADRBK1). Preferably, the organic compounds inhibit the GRK2-mediated phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1, ASF- 1, SF2) and/or phosducin for treating hypertension, heart diseases, heart dysfunction or failure and heart disease-associated pathologies, e.g. cardiomyocyte necrosis, ischemic cardiac disease and/or ischemic heart damage or ageing. Furthermore, the present invention is directed to a method for the identification of inhibitors of the (GRK2)-mediated phosphorylation of (SRSF1) and/or phosducin.

  本发明涉及细胞保护性，特别是心脏和肾脏保护性的有机化合物，优选地指向抑制G蛋白偶联受体激酶2（GRK2，ADRBK1）对底物的磷酸化的有机化合物。优选地，这些有机化合物抑制GRK2介导的丝氨酸/精氨酸富集剪接因子1（SRSF1，ASF-1，SF2）和/或磷酸鸟杜辛的磷酸化，用于治疗高血压、心脏疾病、心脏功能障碍或衰竭以及心脏疾病相关的病理，例如心肌细胞坏死、缺血性心脏病和/或缺血性心脏损伤或衰老。此外，本发明还涉及一种用于识别抑制剂（GRK2）介导的（SRSF1）和/或磷酸鸟杜辛磷酸化的方法。
• US20140275074A1
  申请人：——

  公开号：US20140275074A1

  公开（公告）日：2014-09-18
• US9725442B2
  申请人：——

  公开号：US9725442B2

  公开（公告）日：2017-08-08
• [EN] COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES DU SNC ET DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：ETH ZUERICH

  公开号：WO2019179890A1

  公开（公告）日：2019-09-26

  The present invention is directed to compounds and corresponding pharmaceutical formulations for use in the medical treatment of CNS- and neurodegenerative diseases, for example, for use in the treatment and prophylaxis of familial or sporadic Alzheimer's disease. The invention further relates to corresponding methods of treatment and to a method for determining treatment progression or outcome of senescence and anti-aging treatment based on the detection and/or quantification of Membrane Palmitoylated Protein 1 (MPP1).